Can Targeting Metabolic Pathways Be a Therapeutic Strategy?
Given the distinct metabolic requirements of cancer cells, targeting metabolic pathways offers a promising therapeutic avenue. Inhibitors of glycolysis, glutaminolysis, and lipid metabolism are being explored in preclinical and clinical settings. For example, drugs targeting hexokinase (an enzyme involved in glycolysis) or glutaminase are being investigated for their potential to disrupt cancer cell metabolism. Additionally, dietary interventions and metabolic inhibitors that affect the tumor microenvironment are also being studied to enhance the efficacy of existing treatments.
